Targeting of functional antibody-CD59 fusion proteins to a cell surface

被引:39
作者
Zhang, HF
Yu, JH
Bajwa, E
Morrison, SL
Tomlinson, S
机构
[1] NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA
[2] Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA
关键词
D O I
10.1172/JCI4607
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Complement is involved in the pathogenesis of many diseases, and there is great interest in developing inhibitors of complement for therapeutic application. CD59 is a natural membrane-bound inhibitor of the cytolytic complement membrane attack complex (MAC). In this study, the preparation and characterization of antibody-CD59 (IgG-CD59) chimeric fusion proteins are described. Constructs were com posed of soluble CD59 fused to an antibody-combining site at the end of C(H)1, after the hinge (H), and after C(H)3 Ig regions. The antigen specificity of each construct was for the hapten 5-dimethylaminonaphthalene-1-sulfonyl (dansyl). Correct folding of each IgG-CD59 fusion partner was indicated by recognition with anti-CD59 antibodies specific for conformational determinants and by IgG-CD59 binding to dansyl. The IgG-CD59 fusion proteins all bound specifically to dansyl-labeled Chinese hamster ovary cells and provided targeted cells, but not untargeted cells, with effective protection from complement-mediated lysis. Data indicate that CD59 must be positioned in close proximity to the site of MAC formation for effective function, and that modes of membrane attachment other than glycophosphatidylinositol linkage can affect CD59 functional activity.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 62 条
[1]  
ANDO B, 1989, BLOOD, V73, P462
[2]  
[Anonymous], 1988, Antibodies: A Laboratory Manual
[3]   COMPLEMENT IN ORGAN-TRANSPLANTATION - CONTRIBUTIONS TO INFLAMMATION, INJURY, AND REJECTION [J].
BALDWIN, WM ;
PRUITT, SK ;
BRAUER, RB ;
DAHA, MR ;
SANFILIPPO, F .
TRANSPLANTATION, 1995, 59 (06) :797-808
[4]   Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59 [J].
Bodian, DL ;
Davis, SJ ;
Morgan, BP ;
Rushmere, NK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (03) :507-516
[5]   Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage [J].
Byrne, G ;
McCurry, KR ;
Martin, MJ ;
McClellan, SM ;
Platt, JL ;
Logan, JS .
TRANSPLANTATION, 1997, 63 (01) :149-155
[6]   The role of complement and complement receptors in induction and regulation of immunity [J].
Carroll, MC .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :545-568
[7]  
Challita-Eid PM, 1998, J IMMUNOL, V160, P3419
[8]   REGULATION OF THE COMPLEMENT CASCADE BY SOLUBLE COMPLEMENT RECEPTOR-TYPE-1 - PROTECTIVE EFFECT IN EXPERIMENTAL LIVER ISCHEMIA AND REPERFUSION [J].
CHAVEZCARTAYA, RE ;
DESOLA, GP ;
WRIGHT, L ;
JAMIESON, NV ;
WHITE, DJG .
TRANSPLANTATION, 1995, 59 (07) :1047-1052
[9]  
DANIELS RH, 1990, IMMUNOLOGY, V71, P312
[10]   CD59, AN LY-6-LIKE PROTEIN EXPRESSED IN HUMAN LYMPHOID-CELLS, REGULATES THE ACTION OF THE COMPLEMENT MEMBRANE ATTACK COMPLEX ON HOMOLOGOUS CELLS [J].
DAVIES, A ;
SIMMONS, DL ;
HALE, G ;
HARRISON, RA ;
TIGHE, H ;
LACHMANN, PJ ;
WALDMANN, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (03) :637-654